MLTX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MoonLake Immunotherapeutics (MLTX) is not a strong buy for a beginner, long-term investor at the moment. While there are positive analyst ratings and potential catalysts in the pipeline, the technical indicators are bearish, insider selling raises concerns, and the company’s financial performance remains weak. Given the lack of immediate positive trading signals and uncertain clinical outcomes, holding off on investment is advisable.
The technical indicators for MLTX are bearish. The MACD is negatively expanding below zero, RSI is neutral at 35.366, and the moving averages show a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 16.81, with resistance at 18.036. No clear upward momentum is evident.
Multiple analysts have upgraded the stock with significantly higher price targets, citing confidence in sonelokimab's potential and regulatory progress.
FDA fast track designation for sonelokimab.
Sufficient cash runway into 2H27, providing operational stability.
Insider selling by the CEO, reducing ownership by 4.9%.
Stock decline from a 52-week high due to disappointing clinical trial results.
Analysts have advised caution due to market volatility and uncertain clinical outcomes.
Bearish technical indicators and lack of immediate trading signals.
In Q4 2025, the company reported no revenue growth, a net loss of $62.4 million (improved by 36.89% YoY), and an EPS of -0.92 (up 27.78% YoY). While the financials show improvement in losses, the company remains unprofitable with no revenue generation.
Analysts are generally positive on MLTX, with several upgrades and higher price targets (ranging from $24 to $70). They highlight confidence in sonelokimab's potential, regulatory progress, and upcoming clinical catalysts. However, Goldman Sachs maintains a Sell rating, citing doubts about sonelokimab's approvability and market risks.
